The Top Ten is here, a Sunday fave!! This week we see more variety in our top ten, which is good. ASCO is over and summer is here, so much of the frenzy and hype around a lot of companies has died down a bit. But, that doesn’t mean there’s not gossip to report and research to be done!

OK, here we go with last week’s most read posts — The Top Ten — the posts that made us all laugh, cry, gasp or yell “That IguanaBio is full of s$@!!!! Our drug rocks!!!”

10 – Amgen Expects Denosumab Panel, Confirms Safety Concerns

9 – Pfizer/Wyeth Merger on Track – Maybe?

8 – 16,000 Pink Slips at Merck Post-Merger

7 – More Hamburg, Speaking of Renaissance Technologies…Acorda, Amylin, Pfizer

6 – Arena CEO Jack Lief Speaks, Says Potential Partners Not Interested Until Blossom Data

5 – Belgian Source: Little Interest in Solvay

4 – Cell Therapeutics Note: This Week’s News, Pixantrone Competition and Market Analysis

3 – More Hemispherx Drama

2 – Cell Therapeutics’ Pixantrone: Hype or Truth?

And you guessed it, last week’s most viewed post is our reigning champ…

1 – Did Vatalanib Work for Patrick Swayze?

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts